Cambridge Oncometrix is currently conducting a proof-of-concept clinical investigation to measure the levels of patented biomarkers in prostate-proximal fluids  of healthy volunteers and men having prostatic symptoms.  

Changes in prostatic fluid composition can be used to diagnose cancer, as shown in the chart on the right.